Lack of urokinase plasminogen activator promotes progression and instability of atherosclerotic lesions in apolipoprotein E-knockout mice

Thrombosis and Haemostasis

Volumn 98, Issue 1, 2007, Pages 220-227

  Dellas, Claudia ^a   Schremmer, Carmen ^a   Hasenfuss, Gerd ^a   Konstantinides, Stavros V ^a   Schäfer, Katrin ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Animal models; Arterial thrombosis; Atherosclerosis; Restenosis; Urokinase receptor

Indexed keywords

ALPHA ACTIN; APOLIPOPROTEIN E; COLLAGEN; FERRIC CHLORIDE; FIBRIN; FIBRINOGEN; SMOOTH MUSCLE ACTIN; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRACHIAL ARTERY; BRACHIOCEPHALIC VEIN; CAROTID ARTERY OBSTRUCTION; CELL INVASION; CELL MIGRATION; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; HISTOPATHOLOGY; HYPERLIPOPROTEINEMIA TYPE 3; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CELL MOVEMENT; COLLAGEN; DISEASE PROGRESSION; FIBRIN; HEMORRHAGE; MICE; MICE, KNOCKOUT; URINARY PLASMINOGEN ACTIVATOR;

EID: 34447526532     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-09-0508     Document Type: Article

References (40)

1. Binder BR, Mihaly J, Prager GW. uPAR - uPA - PAI-1 interactions and signaling: A vascular biologist's view. Thromb Haemost 2007; 97: 336-342.
2. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714-724.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4. Lupu F, Heim DA, Bachmann F, et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-1455.
5. Kienast J, Padro T, Steins M, et al. Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb Haemost 1998; 79: 579-586.
6. Padro T, Emeis JJ, Steins M, et al. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995; 15: 893-902.
7. Schäfer K, Konstantinides S, Riedel C, et al. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation 2002; 106: 1847-1852.
8. Carmeliet P, Moons L, Herbert JM, et al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997; 81: 829-839.
9. Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res 1996; 78: 405-414.
10. Clowes AW, Clowes MM, Au YP, et al. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-67.
11. Cozen AE, Moriwaki H, Kremen M, et al. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation 2004; 109: 2129-2135.
12. Falkenberg M, Tom C, DeYoung MB, et al. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion gowth. Proc Natl Acad Sci USA 2002; 99: 10665-10670.
13. Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 2000; 106: 1441-1443.
14. Carmeliet P, Moons L, Dewerchin M, et al. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol 1998; 140: 233-245.
15. Deng G, Curriden SA, Hu G, et al. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 2001; 189: 23-33.
16. Alfano D, Franco P, Vocca I, et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb, Haemost 2005; 93: 205-211.
17. Konstantinides S, Schäfer K, Thinnes T, et al. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 2001; 103: 576-583.
18. Schäfer K, Müller K, Hecke A, et al. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23: 2097-2103.
19. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995; 36: 2320-2328.
20. Paigen B, Morrow A, Holmes PA, et al. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987; 68: 231-240.
21. Calara F, Silvestre M, Casanada F, et al. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol 2001; 195: 257-263.
22. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97: 2433-2444.
23. Johnson J, Carson K, Williams H, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 2005; 111: 1422-1430.
24. Williams H, Johnson JL, Carson KG, et al. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2002; 22: 788-792.
25. Von der Thüsen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001; 103: 1164-1170.
26. Rosenfeld ME, Polinsky P, Virmani R, et al. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol 2000; 20: 2587-2592.
27. Pynn M, Schäfer K, Konstantinides S, et al. Exercise training reduces neointimal growth and stabilizes vascular lesions developing after injury in apolipoprotein E-deficient mice. Circulation 2004; 109: 386-392.
28. Schneiderman J, Bordin GM, Engelberg I, et al. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest 1995; 96: 639-645.
29. Deng GG, Martin-McNulty B, Sukovich DA, et al. Urokinase-type plasminogen activator plays a critical role in angiotensin 11-induced abdominal aortic aneurysm. Circ Res 2003; 92: 510-517.
30. Wang YX, Martin-McNulty B, Freay AD, et al. Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice. Am J Pathol 2001; 159: 1455-1464.
31. Rezaee F, Gijbels M, Offerman E, et al. Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis. Thromb Haemost 2003; 90: 710-716.
32. Strauss BH, Lau HK, Bowman KA, et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999; 100: 1616-1622.
33. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439-444.
34. Carmeliet P, Moons L, Ploplis V, et al. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997; 99: 200-208.
35. Czekay RP, Aertgeerts K, Curriden SA, et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160: 781-791.
36. Cullen P, Baetta R, Bellosta S, et al. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vase Biol 2003; 23: 535-542.
37. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
38. Clarke MC, Figg N, Maguire JJ, et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006; 12: 1075-1080.
39. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103: 934-940.
40. Gyongyosi M, Glogar D, Weidinger F, et al. Association between plasmin activation system and intravascular ultrasound signs of plaque instability inpatients with unstable angina and non-st-segment elevation myocardial infarction. Am Heart J 2004; 147: 158-164.